Within the group of the recognized Polish experts, based on the data from the PL-ACS Registry, for the first time in the world we confirmed that the upfront combination lipid-lowering therapy is superior to statin monotherapy for all-cause mortality in patients with ACS. These results suggest that in high-risk patients, such an approach, rather than a stepwise therapy approach, should be recommended.
